Intra-Cellular Therapies (NASDAQ:ITCI) Announces Earnings Results

Intra-Cellular Therapies (NASDAQ:ITCI) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.15, Briefing.com reports. The business had revenue of $144.90 million for the quarter, compared to the consensus estimate of $141.41 million. Intra-Cellular Therapies had a negative return on equity of 23.02% and a negative net margin of 30.08%. The business’s revenue was up 52.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.46) earnings per share.

Intra-Cellular Therapies Price Performance

Intra-Cellular Therapies stock traded down $1.18 during trading hours on Wednesday, reaching $70.03. The stock had a trading volume of 111,423 shares, compared to its average volume of 924,365. Intra-Cellular Therapies has a 52 week low of $45.50 and a 52 week high of $84.89. The company has a market cap of $6.78 billion, a price-to-earnings ratio of -47.77 and a beta of 1.01. The business’s 50 day moving average price is $69.11 and its 200-day moving average price is $65.85.

Insider Transactions at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 22,590 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $69.79, for a total transaction of $1,576,556.10. Following the transaction, the chief executive officer now directly owns 1,050,309 shares of the company’s stock, valued at $73,301,065.11. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CEO Sharon Mates sold 22,590 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $69.79, for a total transaction of $1,576,556.10. Following the sale, the chief executive officer now directly owns 1,050,309 shares of the company’s stock, valued at $73,301,065.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Suresh K. Durgam sold 6,450 shares of the firm’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $66.56, for a total value of $429,312.00. Following the completion of the transaction, the executive vice president now owns 16,170 shares of the company’s stock, valued at approximately $1,076,275.20. The disclosure for this sale can be found here. Insiders have sold a total of 168,487 shares of company stock valued at $11,364,950 in the last 90 days. Insiders own 3.40% of the company’s stock.

Analyst Ratings Changes

ITCI has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price objective on shares of Intra-Cellular Therapies in a report on Tuesday. Canaccord Genuity Group increased their price target on Intra-Cellular Therapies from $100.00 to $107.00 and gave the company a “buy” rating in a research note on Tuesday, April 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $120.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, April 24th. The Goldman Sachs Group boosted their price target on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 17th. Finally, Bank of America increased their price target on shares of Intra-Cellular Therapies from $82.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Intra-Cellular Therapies has a consensus rating of “Moderate Buy” and a consensus target price of $90.17.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.